Amanda Mikels‐Vigdal
Gilead Sciences (United States)(US)
Publications by Year
Research Areas
Protease and Inhibitor Mechanisms, Microbial metabolism and enzyme function, Peptidase Inhibition and Analysis, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Neonatal Respiratory Health Research
Most-Cited Works
- → Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal(2017)292 cited
- → Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment(2016)264 cited
- → Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer(2015)191 cited
- → Wnt signaling and Loxl2 promote aggressive osteosarcoma(2020)126 cited
- → MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors(2018)103 cited
- → Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis(2020)50 cited
- → Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis(2018)42 cited
- → Therapeutic efficacy of anti‐MMP9 antibody in combination with nab‐paclitaxel‐based chemotherapy in pre‐clinical models of pancreatic cancer(2019)31 cited
- → TGF beta inhibits HGF, FGF7, and FGF10 expression in normal and IPF lung fibroblasts(2018)27 cited
- → Transitional human alveolar type II epithelial cells suppress extracellular matrix and growth factor gene expression in lung fibroblasts(2019)19 cited